Cancer drug resistance : methods and protocols
Discusses the latest techniques used to identify cancer drug resistance determinants at the molecular, cellular, and functional levels. Chapters in this book cover up-to-date topics including tumor-microenvironment cell co-culture methods and microfluidics systems; workflows for functional assessment of drug resistance in vitro and in vivo; quantitative techniques for identifying quiescent blood-flow circulating cells; and single-cell characterization methods, such as mass cytometry.
Cancer drug resistance
In Cancer Drug Resistance, leading scientists from the best academic institutions and industrial laboratories summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to a wide variety of anticancer therapeutics, as well as suggest new approaches to the biology of drug resistance that may afford new therapeutic opportunities.
Cancer cell biology : methods and protocols
Provides detailed methods on the mechanisms of underlying cancer cell biology. Chapters guide readers through techniques for culturing cancer cell lines, xenografts, cryopreservation of tumor cells, analyzing the co-culture of breast cancer cells, protein secretion by ELISA, flow cytometry-based, multi-parametric immunofluorescence analysis, protein expression by western blot, analysis of surface protein levels, protein recycling by biotinylation assay, and proteomics analysis by liquid chromatography-mass spectrometry.
Cancer and Pregnancy
This book is written by experts with clinical expertise on diagnosis, treatment, and follow-up of women with cancer during pregnancy. It provides a comprehensive review of data and an overview of psychological, ethical, and social aspects.
Cancer : Cell Structures, Carcinogens and Genomic Instability
Tumors can be induced by a variety of physical and chemical carcinogens. The resulting tumor cells are usually abnormal in their morphology and behavior and transmit their abnormalities to their daughter tumor cells. Most theories of the pathogenesis of tumors suggest that carcinogens in some way cause alterations either of the genomes or of inheritable patterns of gene expression in normal cells, which then cause morphological and behavioral changes. This volume presents a collection of articles aimed at the question by what genetic or epigenetic mechanisms carcinogens can cause morphological abnormalities of tumor cells. It includes reviews of cellular targets of known carcinogens, and presents varying viewpoints of how morphological abnormalities and the actions of carcinogens might be related.
Breast MRI : Diagnosis and Intervention
This superbly illustrated practical guide is an excellent resource on all aspects of breast MRI for practicing radiologists, oncologists, and surgeons, as well as residents and fellows. Drs. Elizabeth Morris and Laura Liberman, two experts in the field from the Memorial Sloan-Kettering Cancer Center, have collaborated with colleagues from their institution and selected medical centers to share their expertise. Introductory chapters are devoted to diagnosis and cover the basics of performing breast MRI exams, setting up a breast MRI program, and understanding clinical indications. Additional chapters discuss breast interventional procedures including MRI-guided needle localization, MRI-guided biopsy, and percutaneous ablation of breast cancer; MRI of breast implants.
Breast cytopathology
Breast Cytopathology by Syed Ali, MD and Anil Parwani, MD will fulfill the need for an easy-to-use and authoritative synopsis of breast cytopathology. This volume, part of the Essentials in Cytopathology book series, fits into the lab coat pocket and is ideal for portability and quick reference. Each volume in the series is heavily illustrated with a full color art program, while the text follows a user-friendly outline format.
Breast cancer research and treatment : innovative concepts
Focuses on innovative treatment options for breast cancer, including surgery, radiotherapy, systemic therapy and of course immunotherapy that is changing outcomes in some aggressive breast cancer histotypes. Subsequent chapters also address the ongoing emerging research in the screening, diagnostics, and management of all subtypes of breast cancers. All current landscapes and future perspectives in each molecular subtype: luminal, HER2-positive, and triple-negative breast cancers are discussed within the different chapters. Breast cancer is still the most common cancer and cause of cancer deaths among women worldwide. The improvement of breast cancer outcome appears to be strictly related to the validation of precise biomarkers that enable us to better select personalized approaches in breast cancer management. The closing chapters deal with the challenges of low income countries of conducting research in the era of precision medicine for cancer. The book is edited and authored by leading experts in this field and will be of interest for clinicians and scientists alike
Breast cancer genetics, immunology, and immunotherapy : An interdisciplinary approach
Publishes comprehensive volumes on immune and genetic mechanisms of breast cancer diagnosis and prognosis. The role of molecular genetics, interleukins, chemokine receptor, and tumor-infiltrated lymphocytes-TILS in breast cancer are explained. Targeting myeloid determinants, SiRNA loaded in drug delivery nanosystems, nucleic acid and drug dual agent nanoplatforms, and oncolytic virotherapy are also discussed in the treatment of breast cancer, particularly in multidrug resistant and metastatic breast cancer.
Breast cancer chemosensitivity
In Breast Cancer Chemosensitivity, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. Beginning with a clinical overview of the problem Breast Cancer Chemosensitivity moves on to focus on the latest findings of molecular mechanisms of drug resistance. These include in-depth discussions on multidrug resistance by P-glycoprotein and the multidrug resistance protein family, resistance to therapeutic agent-induced apoptosis, cell cycle deregulation, deregulation of DNA repair, loss of tumor suppressor genes, integrin-mediated adhesion, insulin-like growth factors, epidermal growth factor, and ErbB2 in modulating breast cancer response to systemic therapy, especially, certain chemotherapeutic agents. Breast Cancer Chemosensitivity provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment.
Breast cancer ; 2nd ed.
This book highlights M. D. Anderson Cancer Center’s multidisciplinary approach and reviews the entire spectrum of patient care, from prevention and screening through diagnosis and treatment through posttreatment follow-up and survivorship issues.
Brain tumor pathology : Current diagnostic hotspots and pitfalls
Since Bailey and Cushing (1926), all brain tumor classifications have been called histogenetic. The nosographic position that the tumor types progressively acquired in the classification systems derived from the resemblance of tumor cells to those of the cytogenesis, modified whenever new information became available from different biological research fields and especially from molecular genetics. Classically, on the basis of the rough correspondence between the mature/immature aspect of tumor cells and the benign/malignant biological behavior of the tumors, the histological labels contained a prognostic significance. The supposed origin of the tumors was thus a factor for prognosis. Later on, with the concept of anaplasia (Cox, 1933; Kernohan et al., 1949) new criteria were introduced for establishing the malignancy grades of tumors. Immunohistochemistry and later molecular genetics further refined the prognostic diagnoses, substantially increasing the opportunities to recognize the cell origin of tumors, beside revealing the pathogenetic mechanisms. Prognoses became more accurate, as required by the greater and more targeted possibilities of therapy.
Brain Metastases
Brain metastases are the most dreaded complication of systemic cancer, affecting approximately 170,000 people a year, a far greater incidence than primary brain tumors. Advances in modern chemotherapy have led to an improved control of system cancers, often with agents that poorly penetrate the central nervous system, resulting in an increasing incidence of brain metastases. Traditional chemotherapy has had little impact on brain metastases. The main therapeutic option is radiation therapy, and in a small number of patients - surgery. However, refinements in all of these treatments offer some positive outcomes and an increased ability to stratify patients based on certain criteria.
Biologie und epidemiologie der hormonersatztherapie : Diskussionen zur postmenopausalen gesundheit = Biology and epidemiology of hormone replacement therapy : Discussions on postmenopausal health
The advantages and disadvantages of hormone replacement therapy (HRT) are discussed by a group of experts with regard to the epidemiological evidence. However, the focus of the discussion is the problem of breast cancer risk. Among other things, it is shown that the results derived from epidemiological studies do not coincide with the growth characteristics of these tumors, so that further population studies with the inclusion of pathobiological expertise appear necessary. The benefits and risks of hormone replacement therapy (HRT) are discussed by a group of experts with a view towards the evidence provided by recent epidemiological studies. Although all aspects of HRT indications and contra-indications are reviewed, the particular emphasis of this discussion is on breast cancer. Among other things, it is shown that the evidence on breast cancer provided in epidemiological studies does not match the growth characteristics of the tumors, and that further population research incorporating pathobiological assessments is required.
Balloon Kyphoplasty
This book focuses on balloon kyphoplasty and alter- tive minimally invasive treatments for stabilization of osteoporotic vertebral fractures. The optimal treatment of a patient with osteoporotic vertebral fractures requires an interdisciplinary - proach, and therefore our book draws on the expertise of orthopedic surgeons, traumatologists and neu- surgeons, and also includes a chapter on medical treatment.
Aromatase Inhibitors
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
Aromatase Inhibitors
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
Apoptosis, Senescence, and Cancer
Apoptosis, Senescence and Cancer provides insight into established practices and research into apoptosis and senescence by thoroughly examining novel and emerging techniques and research in the fields of cell death pathways, senescence growth arrest, drugs and resistance, DNA damage response, and other topics which still hold mysteries for researchers.this volume provides basic scientists and clinicians with a deeper and more complete understanding of the cellular responses of malignancies which may determine the effectiveness of treatment.
Antiangiogenic Agents in Cancer Therapy
Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other therapies in the armamentarium to fight cancer will be an on-going challenge. Antiangiogenic Agents in Cancer Therapy, Second Edition provides a current, up-dated perspective on the state of the art of angiogenesis and therapy with a compendium of scientific findings and approaches to the study of angiogenesis in cancer. Leaders in the field present chapters on such topics as the environmental influences and the genetic and physiologic abnormalities that mediate angiogenesis and its role in the progression of malignant disease, working models of tumor angiogenesis, and the role of angiogenesis inhibition in the therapy of malignant disease in humans. Comprehensive and cutting-edge, Antiangiogenic Agents in Cancer Therapy, Second Edition is an ideal, valuable guide to the most recent advances in the field, and a collection that will be useful for many years to come.
Angiogenesis in Inflammation : Mechanisms and Clinical Correlates
This volume relates the lessons learned from tumour biology applied to inflammation. This issue of Angiogenesis in Inflammation: Mechanisms and Clinical Correlates develops current knowledge on the mechanisms at the molecular and cellular levels as they relate to inflammation, including acute and chronic inflammation, neurogenic initiation, and the role of the multiple cellular components that comprise inflammation: granulocytes, macrophages, fibroblasts, dendritic cells and lymphocytes. This is related to inflammatory disease: not only the familiar angiogenesis dependent diseases of rheumatoid arthritis and psoriasis, but also loci such as the lung, gastric ulcers, the eye with uveitis, wound healing and periodontal disease and their therapy, how this knowledge may be used in the discovery of novel therapeutics. The volume brings together experts in each of these fields to link the molecular and cellular processes in angiogenesis to those of inflammation and disease, culminating in a discourse on areas for future therapies.



















